Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Association between antidepressant use and breast cancer mortality

From: Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study

  All patients (N = 23,669) Prior depression (N = 5417)a
n Person-years Deaths Unadjusted HR (95% CI) Adjusted HRb (95% CI) n Person-years Deaths Unadjusted HR (95% CI) Adjusted HR (95% CI)
All SSRIs combined
 Never 18,885 105,433 2539 Reference Reference 2861 15,659 435 Reference Reference
 Ever 4784 20,722 514 1.17 (1.07, 1.29) 1.27 (1.16, 1.40) 2556 11,216 294 1.09 (0.93, 1.26) 1.14 (0.98, 1.33)
 1–364 DDDs 2502 12,100 321 1.19 (1.06, 1.34) 1.28 (1.14, 1.44) 1055 5357 160 1.10 (0.92, 1.32) 1.15 (0.96, 1.38)
 365–1094 DDDs 1176 4992 109 1.02 (0.84, 1.24) 1.12 (0.93, 1.36) 701 3167 68 0.87 (0.67, 1.13) 0.91 (0.70, 1.19)
 1095–1824 DDDs 487 1847 47 1.37 (1.03, 1.84) 1.54 (1.15, 2.07) 333 1285 37 1.46 (1.04, 2.07) 1.58 (1.12, 2.24)
 1825+ DDDs 619 1782 37 1.32 (0.95, 1.84) 1.53 (1.10, 2.13) 467 1407 29 1.37 (0.92, 2.03) 1.54 (1.03, 2.29)
Tricyclic antidepressants
 Never 18,734 104,636 2505 Reference Reference 3140 16,608 463 Reference Reference
 Ever 4935 21,519 548 1.25 (1.14, 1.38) 1.30 (1.18, 1.43) 2277 10,267 266 1.08 (0.92, 1.25) 1.07 (0.92, 1.25)
 1–364 DDDs 4041 17,989 464 1.24 (1.12, 1.37) 1.29 (1.17, 1.43) 1583 7509 203 1.05 (0.89, 1.24) 1.06 (0.89, 1.25)
 365–1094 DDDs 574 2416 70 1.50 (1.18, 1.91) 1.51 (1.19, 1.92) 431 1865 53 1.32 (0.99, 1.77) 1.27 (0.94, 1.70)
 1095–1824 DDDs 170 661 9 0.82 (0.43, 1.58) 0.94 (0.49, 1.80) 140 521 6 0.65 (0.29, 1.46) 0.68 (0.30, 1.52)
 1825+ DDDs 150 454 5 0.75 (0.31, 1.81) 0.87 (0.36, 2.10) 123 372 4 0.71 (0.26, 1.92) 0.77 (0.29, 2.08)
Venlafaxine
 Never 22,826 122,227 2968 Reference Reference 4976 24,830 684 Reference Reference
 Ever 843 3928 85 1.02 (0.82, 1.26) 1.30 (1.04, 1.61) 441 2046 45 0.94 (0.69, 1.27) 1.03 (0.76, 1.40)
 1–364 DDDs 522 2531 66 1.19 (0.93, 1.51) 1.64 (1.28, 2.10) 214 1068 29 1.08 (0.74, 1.56) 1.32 (0.91, 1.92)
 365–1094 DDDs 161 861 11 0.60 (0.33, 1.09) 0.67 (0.37, 1.21) 105 557 9 0.67 (0.35, 1.29) 0.66 (0.34, 1.28)
 1095–1824 DDDs 68 293 2 0.36 (0.09, 1.43) 0.36 (0.09, 1.45) 47 227 1 0.22 (0.03, 1.57) 0.20 (0.03, 1.42)
 1825+ DDDs 92 243 6 1.55 (0.70, 3.46) 1.76 (0.79, 3.94) 75 194 6 1.94 (0.86, 4.37) 2.05 (0.91, 4.63)
  1. HR hazard ratio, CI confidence interval, SSRI selective serotonin reuptake inhibitor, DDD defined daily dose
  2. aRestricted to patients with a diagnosis of depression, or prescription of an antidepressant, in the year prior to cancer diagnosis
  3. bAdjusted for age, deprivation, year of diagnosis, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery, tamoxifen, aromatase inhibitors), comorbidities (cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, liver disease, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), hot flushes and pre-diagnosis use of hormone replacement therapy or oral contraceptives